RayStation to Replace Existing Treatment Planning System at NYU Langone Hospital – Long Island

RaySearch Laboratories AB (publ) announces that New York University (NYU) Langone Hospital – Long Island in Mineola, New York, has placed an order for the treatment planning system RayStation®*. The hospital is equipped with Varian linear accelerators, Accuray CyberKnife® and Accuray Radixact® systems, all of which are RayStation compatible.

The installation will provide NYU with advanced automation tools using machine learning techniques for efficient segmentation. Contingency in the clinic will also be enhanced by the feature fallback planning which ensures that alternative treatment plans are available in case a specific machine is not available. Other key RayStation features which will be implemented include multi-criteria optimization, deformable registration, and adaptive treatment planning.

Dr. Matthew Witten, PhD, the Chief Physicist in the Department of Radiation Oncology at NYU Langone Hospital – Long Island, and Director of the hospital’s Division of CyberKnife Radiosurgery says: “We seek to continually implement new technologies in the Department of Radiation Oncology at NYU. RayStation will provide a unified solution for treatment planning across all modalities, including conventional linear accelerators, CyberKnife, Radixact, and high-dose rate brachytherapy. Our goal is to make our department even more efficient, and to further our ability to provide world-class care for our patients.”

Johan Löf, founder and CEO of RaySearch, says: “We are pleased to help NYU Langone – Long Island to enhance treatment quality and efficiency by implementing RayStation for all their treatment techniques and machines.”

Revenue from the order will be recognized in the second quarter of 2023.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.